Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Free Cash Flow (2020 - 2023)

Cullinan Therapeutics has reported Free Cash Flow over the past 4 years, most recently at -$18.1 million for Q4 2023.

  • Quarterly results put Free Cash Flow at -$18.1 million for Q4 2023, up 29.9% from a year ago — trailing twelve months through Dec 2023 was -$134.5 million (down 5.23% YoY), and the annual figure for FY2025 was -$175.8 million, down 20.99%.
  • Free Cash Flow for Q4 2023 was -$18.1 million at Cullinan Therapeutics, up from -$34.1 million in the prior quarter.
  • Over the last five years, Free Cash Flow for CGEM hit a ceiling of -$1.5 million in Q1 2021 and a floor of -$54.6 million in Q3 2022.
  • Median Free Cash Flow over the past 4 years was -$17.2 million (2021), compared with a mean of -$21.0 million.
  • Biggest five-year swings in Free Cash Flow: soared 69.81% in 2021 and later crashed 1346.07% in 2022.
  • Cullinan Therapeutics' Free Cash Flow stood at -$9.4 million in 2020, then crashed by 60.79% to -$15.2 million in 2021, then crashed by 70.49% to -$25.9 million in 2022, then grew by 29.9% to -$18.1 million in 2023.
  • The last three reported values for Free Cash Flow were -$18.1 million (Q4 2023), -$34.1 million (Q3 2023), and -$31.1 million (Q2 2023) per Business Quant data.